Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 6/2019

01-11-2019 | Breast Cancer | Letter to the Editor

Mean platelet volume may not be an independent prognostic factor in breast cancer patients with type 2 diabetes mellitus

Authors: Cengiz Beyan, Esin Beyan

Published in: Breast Cancer | Issue 6/2019

Login to get access

Excerpt

Dear Editor, …
Literature
1.
2.
3.
Jackson SR, Carter JM. Platelet volume: laboratory measurement and clinical application. Blood Rev. 1993;7:104–13.CrossRefPubMed
4.
Metadata
Title
Mean platelet volume may not be an independent prognostic factor in breast cancer patients with type 2 diabetes mellitus
Authors
Cengiz Beyan
Esin Beyan
Publication date
01-11-2019
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2019
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-019-00983-2

Other articles of this Issue 6/2019

Breast Cancer 6/2019 Go to the issue

Original Article

Fatal events during clinical trials: an evaluation of deaths during breast cancer studies

Case Report

Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers

Original Article

Knockdown of FAM64A suppresses proliferation and migration of breast cancer cells

Acknowledgment

Acknowledgements to reviewers 2019

Original Article

Comparison of central sensitization-related symptoms and health-related quality of life between breast cancer survivors with and without chronic pain and healthy controls

Original Article

MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits